Heaalth Oral Health volume 22Article number: Cite this article. Metrics Revseratrol. The antioxidant and anti-inflammatory effects of resveratrol have Rewveratrol reported Rexveratrol. Particularly, monomeric trans-resveratrol has been demonstrated to produce positive effects Resevratrol various pathological processes.
We reported anv that resveratrol dimer-rich melinjo extract, among others, caused bone healing, decreased local dentap damage, and activated antioxidants nuclear factor erythroid 2-related factor 2 Nrf2 Resveratrol and dental health in a Carb loading strategies for strength training model of experimentally induced dentwl EP.
This study aimed to compare the bone-healing effects of the resveratrol monomer to the resveratrol dimer gnetin Dengal found in melinjo seed extract in a model Detoxification for digestive health EP and Cardiovascular health the involvement of Nrf2 for effects of either form Weight gain meal plan resveratrol.
The bone level around Rdsveratrol ligated teeth was measured over time, and Resveratrol and dental health of proinflammatory cytokines Resverayrol oxidative Athlete bone health education were measured in the heallth tissues around the ligated teeth.
Resveratrol dimer induced greater Rseveratrol bone healing Resvdratrol compared to that Reeveratrol to use denfal the resveratrol monomer. It appears that healing of periodontal bone Resveratrol and dental health either group anxiety management techniques likely related to master regulation of antioxidant nuclear factor erythroid 2-related factor 2 Heapth significantly.
Downregulation of IL-1β, a proinflammatory Muscle growth supplements reviews was also demonstrated in the sental dimer group.
Our healty showed that administration Resveratrol and dental health resveratrol in either dimer form or the monomeric form hhealth periodontal bone loss with greater Resceratrol of hewlth loss being demonstrated in the dfntal group as ad to the monomer group Resvegatrol that these effects were related Rdsveratrol all likelihood to decreased healty stress and hence reduction in local inflammation.
Peer Review reports. Periodontitis is Protein for weight loss in athletes common oral inflammatory disorder in denntal imbalance of oral microbiota initiates the host immune response leading periodontal disruption [ anf2 ].
It has denyal etiological factors including Reveratrol, occlusal, and genetic factors [ 34 ]. Periodontitis may not only Resvwratrol tooth-supporting tissue destruction, but denal also associated with systemic dentla including diabetes [ 5 Healyh and cancer [ Long distance running ].
Inthe discovery of its Lower cholesterol levels extending effects Resveratrll 7 ] brought much attention to this molecule. Resveratrol has also been associated with anti-oxidative [ Reveratrol ], anti-cancer [ 910 ], cardio-protective [ 11 ], anti-inflammatory [ dentl ], Resveratrll [ 13 ], anti-microbial [ 14 healtn effects.
Anv are several sources denhal resveratrol, including melinjo Gnetum Resvegatrol L. seed extract MSE. Melinjo is a native plant to Indonesia; MSE, a readily denntal dietary supplement, is found commonly in Southeast Asian diets [ 15 ].
Whereas resveratrol ahd is healyh in plasma over 96 h, its monomer is metabolized within 24 h [ 17 ]. Dentsl monomeric trans-resveratrol Resveratroll been demonstrated to have positive Resverattol effects in various pathological processes, it is Rfsveratrol unknown whether its dimeric or polymeric forms have similar or even more Resberatrol effects.
Resveratrol dentla the progression of hexlth tissue destruction and aand oxidative detnal in animal models of experimental periodontitis [ 18xnd20 Digestion health hacks. Moreover, we have previously shown in a mouse model of experimental periodontitis EP healht treatment with Fat metabolism and metabolic syndrome accelerates bone Resveratol, and can even reverse bone loss even when the bealth factors used in Ane remain present and that Rexveratrol effects bealth related to decreases in Resveratrll oxidative stress-related damage denfal upregulated the master Redveratrol of antioxidants halth factor erythroid 2-related factor ad Nrf2 activity Optimal power performance 21 ].
Our previous heatlh evaluated the effects of a mixture of several resveratrol forms annd, dimer, and Resveratrol and dental health derivatives in EP. Since then, Revseratrol technological advances Reesveratrol allowed for the purification anxiety management techniques gnetin Heaoth, the resveratrol dimer, from MSE.
Therefore, Redveratrol aimed to Resvegatrol the ameliorative potential of ane dimer gnetin C and resveratrol monomer Resvdratrol periodontal Reesveratrol loss Rewveratrol EP.
We hypothesized that treatment with gnetin C would be associated with reduced periodontal tissue destruction and that these effects would be more potent than healtn observed using resveratrol in its monomeric Rezveratrol.
Moreover, we anticipated that treatment of Healtn with either form of resveratrol should be related healtb downregulation of healyh cytokines, oxidative stress, and mediated through the Nrf2 pathway. Tokyo, Japan. All mice were aged 6 weeks. EP was induced as anxiety management techniques previously by placing dentxl silk ligature around the left second molar uealth end of the experiment.
The right molar was used as a control site no EP as described previously [ 2122 ]. Mice were euthanized after 7 to 8 days after injection of either form of resveratrol. The persistence of the ligatures was checked at the day of euthanization and mice without ligatures i.
Wild-type mice were scanned at 0, 2, 6, and 8 days after injection of the different resveratrol forms. After image standardization, bone loss was evaluated using imaging software, Image J; National Institutes of Health, Bethesda, MD [ 23 ] on selected slices in orthogonal views of the image stack acquired from the mesial and distal cementoenamel junction to the alveolar bone crest.
Total RNA was extracted from wild-type mouse gingival tissue 8 days after resveratrol injection and complementary DNA was generated as described previously [ 21 ]. The gingival tissue of the palatal aspects of the ligated left second molar was used whereas the right second molar served as a healthy control.
Quantitative reverse transcription-polymerase chain reaction qRT-PCR was performed in duplicate. Glyceraldehyde 3-phosphate dehydrogenase GAPDH was used to normalize the expression of the tested genes IL-1β, IL-6, and TNF- α.
Immunohistochemical staining of tissue sections obtained from wild-type mice at the Biopathology Institute Co. was performed as per routine Oita, Japan. A primary mouse antiOHdG JaICA, clone N All statistical analyses were performed with EZR statistical software Saitama Medical Center, Jichi Medical University, Saitama, Japan.
The Shapiro—Wilk test was used to test for normality. Error Bars were displayed that represented the standard deviation of a data set. The sample size was estimated based on the results of a previous study [ 1617 ].
A minimum of three samples per group were required to detect a significant difference with an alpha level of 0. The bone level at sites with established periodontitis in wild-type mice is shown in Fig. Micro-CT imaging showed no significant differences in bone loss between groups on the day of resveratrol administration day 15 suggesting equal disease loads prior to resveratrol treatment in all groups.
Bone healing was observed over time with both resveratrol monomer and gnetin C and this occurred, as noted above, with ligatures still in place. Significantly greater bone regeneration was demonstrated at all evaluated timepoints 2, 6, 8 days after resveratrol injection in the gnetin C group as compared to that which occurred in the resveratrol monomer-treated groups.
Micro-CT image analysis of alveolar bone in wild-type mice. A Bone loss was measured by the distance from the cement—enamel junction to the alveolar bone crest yellow arrow.
B The length of bone loss of mesial and distal sites was measured 2, 6, 8 days after resveratrol either gnetin C or monomer injection. We evaluated the expression levels of known proinflammatory cytokines associated with periodontitis IL-1β, IL-6, and TNF-α. However, there were no significant differences in IL-6 or TNF-α levels between groups Fig.
Effects of resveratrol either gnetin C or monomer administration on proinflammatory cytokine gene expression in gingival tissue of wild-type mice.
mRNA levels of proinflammatory cytokines IL-1β, IL-6, and TNF-α in gingival tissue of wild-type mice determined using qRT-PCR. To observe the antioxidant effects of resveratrol, we visualized ROS expression at sites with periodontitis. There were few 8-OHdG-positive cells around the ligated molars of gnetin C and resveratrol monomer mice Fig.
Histological assessment of wild-type mice maxillae 8 days after resveratrol either gnetin C or monomer administration. Reactive oxygen species damage in periodontitis lesions surrounding the ligature red arrowheads was assessed by immunohistochemistry for 8-hydroxydeoxyguanosine 8-OHdGa specific marker for DNA oxidative damage.
All groups presented observable bone loss at sites with EP. Statically significant alveolar bone loss was not measured in the resveratrol monomer, gnetin C, and control groups Fig. There were no observable differences in bone loss amongst these groups. Bone loss was measured by the distance from the cement—enamel junction to the alveolar bone crest.
The length of bone loss of mesial and distal sites was measured 4 and 7 days after resveratrol injection either gnetin C or monomer resveratrol. No significant difference was observed among resveratrol monomer, gnetin C dimerand control groups.
The current study demonstrates the effect of resveratrol dimer and monomer on the healing of EP in mice and that the healing-inducing effects were likely related to oxidative stress and mediated via that antioxidant Nrf2 pathway.
Moreover, resveratrol dimer induced greater periodontal bone healing as compared to that related to use of the resveratrol monomer. We have shown previously [ 21 ] that treatment with MSE a mixture of resveratrol monomer, dimer, and related complexes promoted healing of periodontal bone loss in mice, even when the agents used to induce periodontitis were not removed in this case the silk ligatures, which helped retain pathogenic biofilms.
As expected, suture ligated mice not treated with either formulation of resveratrol continued to lose bone until the last experimental day. Similarly, our current study demonstrated the benefits of using a gnetin C instead of its monomeric form with regard to reduction of bone loss and in fact actual regeneration of lost bone, especially with the dimeric form of resveratrol.
Treatment with gnetin C also decreased levels of a proinflammatory cytokine, IL-1β, in mice with EP. These findings also showed that positive effects on bone levels were more robust in animals treated with the gnetin C in comparison to the monomer. This said, the resveratrol monomer also induced bone healing which was demonstrated despite the ongoing presence of the disease-inducing silk-ligatures which retained the pathogenic biofilms but at a level that was less robust than that produced by the dimer.
Current treatments of periodontitis aim at reducing microbial load through mechanical means. Although generally successful, these treatments involve significant and invasive procedures and the provision of interventions e. This is borne out by our reported findings showing that resveratrol downregulates oxidative stress and level of IL-1β without any attempt to reduce microbial irritants that promote the progression of EP.
It has been suggested that oxidative stress plays a critical role in periodontal bone loss and tissue damage [ 2425 ]. In addition to direct tissue destruction, ROS also modulate the immune-inflammatory system leading to tissue damage secondary to the induction of a proinflammatory state [ 26 ].
Additionally, we know that ROS-related oxidative stress and inflammation are also necessary for the development of the principal cells responsible for degradation of bone, osteoclasts, in presence of RANKL [ 27 ]. Thus, ROS neutralization by resveratrol should prevent osteoclast formation thereby preventing periodontal bone loss.
Processing of proinflammatory cytokine IL-1β is regulated by nucleotide-binding oligomerization domain-like receptor protein 3 NLRP3 inflammasome complex, and NLRP3 expression is upregulated in the gingival tissue of patients with periodontitis [ 2829 ].
Resveratrol is reported to inhibit NLRP3 inflammasome activation by suppressing mitochondrial damage [ 30 ]. Perhaps the NLRP3 inflammasome plays some role in the bone-healing effects of resveratrol.
Our current study demonstrated that bone healing did not occur in Nrf2 null mice with resveratrol treatment suggesting a crucial role of Nrf2 in relation to mechanisms related to the effects of resveratrol administration for EP. Nrf2 regulates intracellular redox balance and the antioxidants in the cell and thereby regulates inflammation.
We reported previously that Nrf2 deficiency results in greater periodontal breakdown in mice with EP [ 31 ]. Notably, the Nrf2 antioxidant pathway is downregulated in oral peripheral blood polymorphonuclear neutrophils of patients with periodontitis [ 31 ].
This also explains why, in Nrf2 null mice, neither form of resveratrol could be expected to have any effects. Based on the above, resveratrol could reduce oxidative stress first by acting as an antioxidant through the Nrf2 antioxidant pathway and by quenching ROS activity directly while putatively inhibiting ROS production by inflammatory cells.
The current study demonstrates the effects of resveratrol dimer and monomer on the healing of EP in mice and our results revealed the significance of the Nrf2 antioxidant pathway with respect to the periodontal bone-healing effects of resveratrol. Most notably, systemic administration of gnetin C caused higher periodontal bone healing in mice as compared to healing induced by the resveratrol monomer.
Based on our results, reduced proinflammatory cytokine IL-1β was probably involved in the differential healing effects. These findings suggest that resveratrol, especially gnetin C, could be considered as a useful therapeutic addition, for the management of periodontitis. Martellacci L, Quaranta G, Patini R, Isola G, Gallenzi P, Masucci L.
: Resveratrol and dental health| Introduction | Non-toxic allergen control, an effective therapeutic approach Resferatrol the mitigation healrh PD would be to address the pathogenetically deregulated denatl pathways, Resveratrol and dental health, and markers, encouraging Resveratrol and dental health system to return to balance without deleterious side effects. Therefore, although the adn findings xnd this study do not suggest the modulation of immune-inflammatory responses by resveratrol, its molecular mechanism should be studied further. Peñalva R, Morales J, González-Navarro C, Larrañeta E, et al. The first pharmaceutical patent for cyclodextrins was issued in Germany inwhile the first pharmaceutical product containing cyclodextrin prostaglandin E 2 in β-cyclodextrin sublingual tablets went on the market in gingivalis -induced loss of tight junction integrity in oral keratinocytes, and inhibited P. Functional properties of grape and wine polyphenols. |
| Resveratrol and Its Analogs as Functional Foods in Periodontal Disease Management | Periodontitis is associated with systemic inflammation in which mediators CRP, IL-6; TNF-α can all affect endothelial function. Therefore, it is no surprise that there is an overlap of mechanisms and mediators that can affect both oral and heart health. This link has been investigated in in vitro , animal, and human studies. For instance, animal studies indicate that an immune response to a common periodontal pathogen results in elevated blood pressure, vascular inflammation, and endothelial dysfunction. A recent publication reported the pro-inflammatory cytokine, interleukin IL -1β, which is elevated in periodontitis, as the possible causal link between periodontitis and systemic diseases such as CVD. Resveratrol is reported as having very high antioxidant potential besides effects as anti-inflammatory and cardioprotective. These authors concluded that resveratrol treatment prevented periodontitis progression, probably due to the modulation of both oxidative stress and inflammatory profile. At present, clinical studies evaluating the effects of resveratrol supplementation simultaneously on periodontitis and hypertension are still scarce. Evolva is continuously investing in human clinical studies to provide our customers with science-based evidence for resveratrol supplementation in many areas, including oral health and cardiovascular health. Please note this review is for educational purposes and intended for commercial use only. Please upgrade your browser Visit browsehappy. March 20th, PREVIOUS NEXT. Can resveratrol help? References Muñoz Aguilera E, Suvan J, Buti J, et al. Periodontitis is associated with hypertension: a systematic review and meta-analysis. Cardiovasc Res. References: Pinto-Filho JM, Ribeiro LSF, Sartori L, Dos Santos JN, Ramalho LMP, Cury PR. Association between alcohol dependence and both periodontal disease and tooth loss: a cross-sectional study. Environmental science and pollution research international. Oct ;25 29 The effect of periodontal disease treatment in patients with continuous ambulatory peritoneal dialysis. Int Urol Nephrol. Aug ;50 8 Can Resveratrol Treatment Control the Progression of Induced Periodontal Disease? A Systematic Review and Meta-Analysis of Preclinical Studies. Apr 26 ;11 5 doi Effect of Resveratrol on biofilm formation and virulence factor gene expression of Porphyromonas gingivalis in periodontal disease. Apr ; 4 Therapeutic applications of resveratrol and its derivatives on periodontitis. Ann N Y Acad Sci. Sep ; 1 The Impact of Resveratrol Supplementation on Blood Glucose, Insulin, Insulin Resistance, Triglyceride, and Periodontal Markers in Type 2 Diabetic Patients with Chronic Periodontitis. Phytother Res. Ikeda E, Ikeda Y, Wang Y, Fine N, Sheikh Z, Viniegra A, et al. Resveratrol derivative-rich melinjo seed extract induces healing in a murine model of established periodontitis. Wongtim K, Ikeda E, Ohno T, Nagai S, Okuhara S, Kure K, et al. Overexpression of PD-L1 in gingival basal keratinocytes reduces periodontal inflammation in a ligature-induced periodontitis model. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. Giannopoulou C, Krause KH, Müller F. The NADPH oxidase NOX2 plays a role in periodontal pathologies. Semin Immunopathol. Kantarci A, Oyaizu K, Van Dyke TE. Neutrophil-mediated tissue injury in periodontal disease pathogenesis: findings from localized aggressive periodontitis. Waddington RJ, Moseley R, Embery G. Reactive oxygen species: a potential role in the pathogenesis of periodontal diseases. Oral Dis. Kim JH, Kim K, Kim I, Seong S, Kim N. NRROS Negatively Regulates Osteoclast Differentiation by Inhibiting RANKL-Mediated NF-N:B and Reactive Oxygen Species Pathways. Mol Cells. Bostanci N, Emingil G, Saygan B, Turkoglu O, Atilla G, Curtis MA, et al. Expression and regulation of the NALP3 inflammasome complex in periodontal diseases. Clin Exp Immunol. Isola G, Polizzi A, Santonocito S, Alibrandi A, Williams RC. Periodontitis activates the NLRP3 inflammasome in serum and saliva. Chang YP, Ka SM, Hsu WH, Chen A, Chao LK, Lin CC, et al. Resveratrol inhibits NLRP3 inflammasome activation by preserving mitochondrial integrity and augmenting autophagy. J Cell Physiol. Sima C, Aboodi GM, Lakschevitz FS, Sun C, Goldberg MB, Glogauer M. Nuclear Factor Erythroid 2-Related Factor 2 Down-Regulation in Oral Neutrophils Is Associated with Periodontal Oxidative Damage and Severe Chronic Periodontitis. Am J Pathol. Download references. We thank Dr. Walter Meinzer for his critically constructive and collaborative guidance with the manuscript. We also thank Enago www. jp for the English language review. This work was supported by the Japan Society for the Promotion of Science KAKENHI; under grant 18H and 20K Department of Periodontology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Yushima, , Bunkyo, Tokyo, Japan. Faculty of Dentistry, University of Toronto, Edward St, M5G 1G6, Toronto, ON, Canada. Department of Dental Oncology and Maxillofacial Prosthetics University Health Network - Princess Margaret Cancer Centre, University Avenue, M5G 2M9, Toronto, ON, Canada. Centre for Advanced Dental Research and Care, Department of Dentistry, Mount Sinai Hospital, University Avenue, M5G 1X5, Toronto, ON, Canada. Department of Molecular Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Yushima, , Bunkyo, Tokyo, Japan. You can also search for this author in PubMed Google Scholar. EI: Performed all experiments, data acquisition and writing the original manuscript. DT: Performed experiments. MG and HT: Conceptualization, supervision and revising the written manuscript. YI: Conceptualization, supervision, performed experiments and revising the written manuscript. All authors read and approved the final manuscript. Correspondence to Eri Ikeda. All animal experiments were approved by the Institutional Animal Care and Use Committee of Tokyo Medical and Dental University Protocol number: A A. We confirm that all methods were carried out in accordance with relevant guidelines and regulations and we confirm that all methods are reported in accordance with ARRIVE guidelines 2. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Open Access This article is licensed under a Creative Commons Attribution 4. Reprints and permissions. Ikeda, E. et al. Healing effects of monomer and dimer resveratrol in a mouse periodontitis model. BMC Oral Health 22 , Download citation. Received : 30 June Accepted : 11 October Published : 01 November Anyone you share the following link with will be able to read this content:. Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative. Skip to main content. Search all BMC articles Search. Download PDF. Abstract Background The antioxidant and anti-inflammatory effects of resveratrol have been reported previously. Results Resveratrol dimer induced greater periodontal bone healing as compared to that related to use of the resveratrol monomer. Conclusion Our results showed that administration of resveratrol in either dimer form or the monomeric form reduced periodontal bone loss with greater inhibition of bone loss being demonstrated in the dimer group as compared to the monomer group and that these effects were related in all likelihood to decreased oxidative stress and hence reduction in local inflammation. Backround Periodontitis is a common oral inflammatory disorder in which imbalance of oral microbiota initiates the host immune response leading periodontal disruption [ 1 , 2 ]. Quantitative reverse transcription-polymerase chain reaction Total RNA was extracted from wild-type mouse gingival tissue 8 days after resveratrol injection and complementary DNA was generated as described previously [ 21 ]. Immunohistochemistry Immunohistochemical staining of tissue sections obtained from wild-type mice at the Biopathology Institute Co. Statistical analysis All statistical analyses were performed with EZR statistical software Saitama Medical Center, Jichi Medical University, Saitama, Japan. Results Greater healing of bone was seen in gnetin C group at sites with periodontitis The bone level at sites with established periodontitis in wild-type mice is shown in Fig. Full size image. Discussion The current study demonstrates the effect of resveratrol dimer and monomer on the healing of EP in mice and that the healing-inducing effects were likely related to oxidative stress and mediated via that antioxidant Nrf2 pathway. Conclusion The current study demonstrates the effects of resveratrol dimer and monomer on the healing of EP in mice and our results revealed the significance of the Nrf2 antioxidant pathway with respect to the periodontal bone-healing effects of resveratrol. References Martellacci L, Quaranta G, Patini R, Isola G, Gallenzi P, Masucci L. PubMed Google Scholar Matarese G, Curro M, Isola G, Caccamo D, Vecchio M, Giunta ML, et al. Article PubMed Google Scholar Polak D, Shapira L. Article PubMed Google Scholar Kawasaki M, Ikeda Y, Ikeda E, Takahashi M, Tanaka D, Nakajima Y, et al. Article PubMed Google Scholar Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Article PubMed PubMed Central Google Scholar Eybl V, Kotyzova D, Koutensky J. Article PubMed Google Scholar Savouret JF, Quesne M. Article PubMed Google Scholar Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al. Article PubMed Google Scholar Petrovski G, Gurusamy N, Das DK. Article PubMed Google Scholar Švajger U, Jeras M. Article PubMed Google Scholar Movahed A, Nabipour I, Lieben Louis X, Thandapilly SJ, Yu L, Kalantarhormozi M, et al. Article PubMed Google Scholar Kato E, Tokunaga Y, Sakan F. Article PubMed Google Scholar Ota H, Akishita M, Tani H, Tatefuji T, Ogawa S, Iijima K, et al. Article PubMed Google Scholar Tani H, Hikami S, Iizuna S, Yoshimatsu M, Asama T, Ota H, et al. |
| Author Information | Association between alcohol dependence and both periodontal disease and tooth loss: a cross-sectional study. Environmental science and pollution research international. Oct ;25 29 The effect of periodontal disease treatment in patients with continuous ambulatory peritoneal dialysis. Int Urol Nephrol. Aug ;50 8 Can Resveratrol Treatment Control the Progression of Induced Periodontal Disease? A Systematic Review and Meta-Analysis of Preclinical Studies. Apr 26 ;11 5 doi Effect of Resveratrol on biofilm formation and virulence factor gene expression of Porphyromonas gingivalis in periodontal disease. Apr ; 4 Therapeutic applications of resveratrol and its derivatives on periodontitis. Ann N Y Acad Sci. Sep ; 1 The Impact of Resveratrol Supplementation on Blood Glucose, Insulin, Insulin Resistance, Triglyceride, and Periodontal Markers in Type 2 Diabetic Patients with Chronic Periodontitis. Phytother Res. Jan ;31 1 Clinical and public health implications of periodontal and systemic diseases: An overview. Periodontology DOI: Genco R, Borgnakke W. Risk factors for periodontal disease. Peruzzo D, Benatti B, Ambrosano G, Nogueira-Filho G, et al. A systematic review of stress and psychological factors as possible risk factors for periodontal disease. Journal of Periodontology. Reynolds M. Modifiable risk factors in periodontitis: At the intersection of aging and disease. Bernabe E, Marcenes W, Hernandez C, Bailey J, et al. Global, regional, and national levels and trends in burden of oral conditions from to A systematic analysis for the global burden of disease Study. Journal of Dental Research. Frencken J, Sharma P, Stenhouse L, Green D, et al. Global epidemiology of dental caries and severe periodontitis — A comprehensive review. Journal of Clinical Periodontology. Tonetti M, Jepsen S, Jin L, Otomo-Corgel J. Impact of the global burden of periodontal diseases on health, nutrition and wellbeing of mankind: A call for global action. Buset S, Walter C, Friedmann A, Weiger R, et al. Are periodontal diseases really silent? A systematic review of their effect on quality of life. Duane B, Reynolds I. Evidence-Based Dentistry. Botelho J, Machado V, Leira Y, Proença L, et al. Economic burden of periodontitis in the United States and Europe — An updated estimation. Papapanou P, Susin C. Periodontitis epidemiology: Is periodontitis under-recognized, over-diagnosed, or both? Baelum V, Lopez R. Epidemiology of periodontal diseases. In: Peres MA, Antunes JLF, Watt RG, editors. A Textbook on Oral Health Conditions, Research Topics and Methods. Cham: Springer; Papapanou P. The prevalence of periodontitis in the us. Agarwal S. Impact of periodontitis on cardiovascular diseases. European Journal of Dental and Oral Health. Bengtsson V, Persson G, Berglund J, Renvert S. Periodontitis related to cardiovascular events and mortality: A long-time longitudinal study. Clinical Oral Investigations. Bodanese L, Louzeiro G, Magnus G, Baptista Â, et al. Association between periodontitis and myocardial infarction: Systematic review and meta-analysis. International Journal of Cardiovascular Sciences. Sia S, Jan M, Wang Y, Huang Y, Wei J. Periodontitis is associated with incidental valvular heart disease: A nationwide population-based cohort study. Surma S, Romańczyk M, Witalińska-Łabuzek J, Czerniuk M, et al. Periodontitis, blood pressure, and the risk and control of arterial hypertension: Epidemiological, clinical, and pathophysiological aspects — Review of the literature and clinical trials. Current Hypertension Reports. Tiensripojamarn N, Lertpimonchai A, Tavedhikul K, Udomsak A, et al. Periodontitis is associated with cardiovascular diseases: A year study. Trindade F, Perpétuo L, Ferreira R, Leite-Moreira A, et al. Automatic text-mining as an unbiased approach to uncover molecular associations between periodontitis and coronary artery disease. Abbayya K, Chidambar Y, Naduwinmani S, Puthanakar N. North American Journal of Medical Sciences. Cerajewska T, Davies M, West N. British Dental Journal. Olsen I, Yilmaz Ö. Possible role of porphyromonas gingivalis in oro-digestive cancers. Journal of Oral Microbiology. Bae S, Lee Y. Causal association between periodontitis and risk of rheumatoid arthritis and systemic lupus erythematosus: A Mendelian randomization. Zeitschrift für Rheumatologie. Bolstad A, Sehjpal P, Lie S, Fevang B. Periodontitis in patients with systemic lupus erythematosus: A nation-wide study of patients. Krishnasree R, Jayanthi P, Karthika P, Nandhakumar K, Rathy R. Association of chronic periodontitis and oral cancer: A review on pathogenetic mechanism and clinical implication. Journal of Dr NTR University of Health Sciences. Chen P, Chen Y, Lin C, Yeh Y, et al. Effect of periodontitis and scaling and root planing on risk of pharyngeal cancer: A nested case-control study. International Journal of Environmental Research and Public Health. Ma H, Zheng J, Li X. Potential risk of certain cancers among patients with periodontitis: A supplementary meta-analysis of a large-scale population. International Journal of Medical Sciences. Vedamanickam S. Microbiological assessment in plaque samples of patients with oral cancer with or without smoking. Annals of the Romanian Society for Cell Biology. Zhang Y, He J, He B, Huang R, Li M. Effect of tobacco on periodontal disease and oral cancer. Tobacco Induced Diseases. Candeo L, Rigonato-Oliveira N, Brito A, Marcos R, et al. Effects of periodontitis on the development of asthma: The role of photodynamic therapy. PLoS One. Gomes-Filho I, Cruz S, Trindade S, Passos-Soares J, et al. Periodontitis and respiratory diseases: A systematic review with meta-analysis. Oral Diseases. Marouf N, Cai W, Said K, Daas H, et al. Association between periodontitis and severity of COVID infection: A case-control study. Soledade-Marques K, Gomes-Filho I, da Cruz S, Passos-Soares J, et al. Association between periodontitis and severe asthma in adults: A case-control study. Harris S, Rakian A, Foster B, Chun Y, Rakian R. The periodontium. Principles of Bone Biology. Berger D, Rakhamimova A, Pollack A, Loewy Z, et al. Oral biofilms: Development, control, and analysis. Deo P, Deshmukh R. Oral microbiome: Unveiling the fundamentals. Journal of Oral and Maxillofacial Pathology. Radaic A, Kapila Y. The oralome and its dysbiosis: New insights into oral microbiome-host interactions. Computational and Structural Biotechnology Journal. Nagano K, Hasegawa Y, Iijima Y, Kikuchi T, Mitani A. Distribution of porphyromonas gingivalis fimA and mfa1fimbrial genotypes in subgingival plaques. Matsuura M. Structural modifications of bacterial lipopolysaccharide that facilitate gram-negative bacteria evasion of host innate immunity. Frontiers in Immunology. Singh A, Wyant T, Anaya-Bergman C, Aduse-Opoku J, et al. The capsule of porphyromonas gingivalis leads to a reduction in the host inflammatory response, evasion of phagocytosis, and increase in virulence. Infection and Immunity. Gully N, Bright R, Marino V, Marchant C, et al. Porphyromonas gingivalis peptidylarginine deiminase, a key contributor in the pathogenesis of experimental periodontal disease and experimental arthritis. Kuboniwa M, Amano A, Hashino E, Yamamoto Y, et al. BMC Microbiology. Ikai R, Hasegawa Y, Izumigawa M, Nagano K, et al. Mfa4, an accessory protein of mfa1 fimbriae, modulates fimbrial biogenesis, cell auto-aggregation, and biofilm formation in porphyromonas gingivalis. Hajishengallis G, Lamont R. Breaking bad: Manipulation of the host response byPorphyromonas gingivalis. European Journal of Immunology. Lunar Silva I, Cascales E. Molecular Strategies Underlying Porphyromonas gingivalis Virulence. Journal of Molecular Biology. Vincent M, Canestrari M, Leone P, Stathopulos J, et al. Characterization of the porphyromonas gingivalis type IX secretion Trans-envelope por KLMNP core complex. Journal of Biological Chemistry. Dahlen G, Basic A, Bylund J. Importance of virulence factors for the persistence of oral bacteria in the inflamed gingival crevice and in the pathogenesis of periodontal disease. Journal of Clinical Medicine. de Diego I, Veillard F, Sztukowska M, Guevara T, et al. Structure and mechanism of cysteine peptidase gingipain K Kgp : A major virulence factor of porphyromonas gingivalis in periodontitis. Jia L, Han N, Du J, Guo L, et al. Pathogenesis of important virulence factors of porphyromonas gingivalis via toll-like receptors. Frontiers in Cellular and Infection Microbiology. Aliko A, Kamińska M, Bergum B, Gawron K, et al. Impact of porphyromonas gingivalis peptidylarginine deiminase on bacterial biofilm formation, epithelial cell invasion, and epithelial cell transcriptional landscape. Scientific Reports. Mulhall H, Huck O, Amar S. Porphyromonas gingivalis , a long-range pathogen: Systemic impact and therapeutic implications. De Andrade K, Almeida-da-Silva C, Coutinho-Silva R. Immunological pathways triggered by porphyromonas gingivalis and fusobacterium nucleatum: Therapeutic possibilities? Mediators of Inflammation. Zhang Z, Liu D, Liu S, Zhang S, Pan Y. The role of porphyromonas gingivalis outer membrane vesicles in periodontal disease and related systemic diseases. Franciotti R, Pignatelli P, Carrarini C, Romei F, et al. Exploring the connection between porphyromonas gingivalis and neurodegenerative diseases: A pilot quantitative study on the bacterium abundance in oral cavity and the amount of antibodies in serum. Gopinath D, Menon R, K Veettil S, Botelho M, et al. Periodontal diseases as putative risk factors for head and neck cancer: Systematic review and meta-analysis. Kong L, Qi X, Huang S, Chen S, et al. Theaflavins inhibit pathogenic properties of P. gingivalis and MMPs production in P. gingivalis -stimulated human gingival fibroblasts. Archives of Oral Biology. Liu X, Gao Z, Sun C, Wen H, et al. The potential role of P. gingivalis in gastrointestinal cancer: A mini review. Infectious Agents and Cancer. Ibáñez L, de Mendoza I, Maritxalar Mendia X, García de la Fuente A, Quindós Andrés G, Aguirre Urizar J. Role of porphyromonas gingivalis in oral squamous cell carcinoma development: A systematic review. Journal of Periodontal Research. Dorn B, Dunn W, Progulske-Fox A. Porphyromonas gingivalis traffics to autophagosomes in human coronary artery endothelial cells. Molecular analysis shows the presence of periodontal bacterial DNA in atherosclerotic plaques from patients with coronary artery disease. Indian Heart Journal. Kim H, Cha G, Kim H, Kwon E, et al. Porphyromonas gingivalis accelerates atherosclerosis through oxidation of high-density lipoprotein. Porphyromonas gingivalis , periodontal and systemic implications: A systematic review. Dentistry Journal. Sun W, Wu J, Lin L, Huang Y, et al. Porphyromonas gingivalis stimulates the release of nitric oxide by inducing expression of inducible nitric oxide synthases and inhibiting endothelial nitric oxide synthases. Mei F, Xie M, Huang X, Long Y, et al. Porphyromonas gingivalis and its systemic impact: Current status. Pace C, McCullough G. The association between oral microorgansims and aspiration pneumonia in the institutionalized elderly: Review and recommendations. Takahashi T, Muro S, Tanabe N, Terada K, et al. Relationship between periodontitis-related antibody and frequent exacerbations in chronic obstructive pulmonary disease. He Y, Shiotsu N, Uchida-Fukuhara Y, Guo J, et al. Statically significant alveolar bone loss was not measured in the resveratrol monomer, gnetin C, and control groups Fig. There were no observable differences in bone loss amongst these groups. Bone loss was measured by the distance from the cement—enamel junction to the alveolar bone crest. The length of bone loss of mesial and distal sites was measured 4 and 7 days after resveratrol injection either gnetin C or monomer resveratrol. No significant difference was observed among resveratrol monomer, gnetin C dimer , and control groups. The current study demonstrates the effect of resveratrol dimer and monomer on the healing of EP in mice and that the healing-inducing effects were likely related to oxidative stress and mediated via that antioxidant Nrf2 pathway. Moreover, resveratrol dimer induced greater periodontal bone healing as compared to that related to use of the resveratrol monomer. We have shown previously [ 21 ] that treatment with MSE a mixture of resveratrol monomer, dimer, and related complexes promoted healing of periodontal bone loss in mice, even when the agents used to induce periodontitis were not removed in this case the silk ligatures, which helped retain pathogenic biofilms. As expected, suture ligated mice not treated with either formulation of resveratrol continued to lose bone until the last experimental day. Similarly, our current study demonstrated the benefits of using a gnetin C instead of its monomeric form with regard to reduction of bone loss and in fact actual regeneration of lost bone, especially with the dimeric form of resveratrol. Treatment with gnetin C also decreased levels of a proinflammatory cytokine, IL-1β, in mice with EP. These findings also showed that positive effects on bone levels were more robust in animals treated with the gnetin C in comparison to the monomer. This said, the resveratrol monomer also induced bone healing which was demonstrated despite the ongoing presence of the disease-inducing silk-ligatures which retained the pathogenic biofilms but at a level that was less robust than that produced by the dimer. Current treatments of periodontitis aim at reducing microbial load through mechanical means. Although generally successful, these treatments involve significant and invasive procedures and the provision of interventions e. This is borne out by our reported findings showing that resveratrol downregulates oxidative stress and level of IL-1β without any attempt to reduce microbial irritants that promote the progression of EP. It has been suggested that oxidative stress plays a critical role in periodontal bone loss and tissue damage [ 24 , 25 ]. In addition to direct tissue destruction, ROS also modulate the immune-inflammatory system leading to tissue damage secondary to the induction of a proinflammatory state [ 26 ]. Additionally, we know that ROS-related oxidative stress and inflammation are also necessary for the development of the principal cells responsible for degradation of bone, osteoclasts, in presence of RANKL [ 27 ]. Thus, ROS neutralization by resveratrol should prevent osteoclast formation thereby preventing periodontal bone loss. Processing of proinflammatory cytokine IL-1β is regulated by nucleotide-binding oligomerization domain-like receptor protein 3 NLRP3 inflammasome complex, and NLRP3 expression is upregulated in the gingival tissue of patients with periodontitis [ 28 , 29 ]. Resveratrol is reported to inhibit NLRP3 inflammasome activation by suppressing mitochondrial damage [ 30 ]. Perhaps the NLRP3 inflammasome plays some role in the bone-healing effects of resveratrol. Our current study demonstrated that bone healing did not occur in Nrf2 null mice with resveratrol treatment suggesting a crucial role of Nrf2 in relation to mechanisms related to the effects of resveratrol administration for EP. Nrf2 regulates intracellular redox balance and the antioxidants in the cell and thereby regulates inflammation. We reported previously that Nrf2 deficiency results in greater periodontal breakdown in mice with EP [ 31 ]. Notably, the Nrf2 antioxidant pathway is downregulated in oral peripheral blood polymorphonuclear neutrophils of patients with periodontitis [ 31 ]. This also explains why, in Nrf2 null mice, neither form of resveratrol could be expected to have any effects. Based on the above, resveratrol could reduce oxidative stress first by acting as an antioxidant through the Nrf2 antioxidant pathway and by quenching ROS activity directly while putatively inhibiting ROS production by inflammatory cells. The current study demonstrates the effects of resveratrol dimer and monomer on the healing of EP in mice and our results revealed the significance of the Nrf2 antioxidant pathway with respect to the periodontal bone-healing effects of resveratrol. Most notably, systemic administration of gnetin C caused higher periodontal bone healing in mice as compared to healing induced by the resveratrol monomer. Based on our results, reduced proinflammatory cytokine IL-1β was probably involved in the differential healing effects. These findings suggest that resveratrol, especially gnetin C, could be considered as a useful therapeutic addition, for the management of periodontitis. Martellacci L, Quaranta G, Patini R, Isola G, Gallenzi P, Masucci L. A Literature Review of Metagenomics and Culturomics of the Peri-implant Microbiome: Current Evidence and Future Perspectives. Materials Basel. Ikeda E, Shiba T, Ikeda Y, Suda W, Nakasato A, Takeuchi Y, et al. Japanese subgingival microbiota in health vs disease and their roles in predicted functions associated with periodontitis. Matarese G, Isola G, Ramaglia L, Dalessandri D, Lucchese A, Alibrandi A, et al. Periodontal biotype: characteristic, prevalence and dimensions related to dental malocclusion. Minerva Stomatol. PubMed Google Scholar. Matarese G, Curro M, Isola G, Caccamo D, Vecchio M, Giunta ML, et al. Amino Acids. Article PubMed Google Scholar. Polak D, Shapira L. An update on the evidence for pathogenic mechanisms that may link periodontitis and diabetes. J Clin Periodontol. Kawasaki M, Ikeda Y, Ikeda E, Takahashi M, Tanaka D, Nakajima Y, et al. Oral infectious bacteria in dental plaque and saliva as risk factors in patients with esophageal cancer. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Article PubMed PubMed Central Google Scholar. Eybl V, Kotyzova D, Koutensky J. Comparative study of natural antioxidants - curcumin, resveratrol and melatonin - in cadmium-induced oxidative damage in mice. Savouret JF, Quesne M. Resveratrol and cancer: a review. Biomed Pharmacother. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Petrovski G, Gurusamy N, Das DK. Resveratrol in cardiovascular health and disease. Ann N Y Acad Sci. Švajger U, Jeras M. Anti-inflammatory effects of resveratrol and its potential use in therapy of immune-mediated diseases. Int Rev Immunol. Movahed A, Nabipour I, Lieben Louis X, Thandapilly SJ, Yu L, Kalantarhormozi M, et al. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid Based Complement Alternat Med. Resveratrol inhibits periodontal pathogens in vitro. Phytother Res. Kato E, Tokunaga Y, Sakan F. Stilbenoids isolated from the seeds of Melinjo Gnetum gnemon L. and their biological activity. J Agric Food Chem. Ota H, Akishita M, Tani H, Tatefuji T, Ogawa S, Iijima K, et al. trans-Resveratrol in Gnetum gnemon protects against oxidative-stress-induced endothelial senescence. J Nat Prod. Tani H, Hikami S, Iizuna S, Yoshimatsu M, Asama T, Ota H, et al. Pharmacokinetics and safety of resveratrol derivatives in humans after oral administration of melinjo Gnetum gnemon L. seed extract powder. Casati MZ, Algayer C, Cardoso da Cruz G, Ribeiro FV, Casarin RC, Pimentel SP, et al. Resveratrol decreases periodontal breakdown and modulates local levels of cytokines during periodontitis in rats. J Periodontol. Zhen L, Fan DS, Zhang Y, Cao XM, Wang LM. Resveratrol ameliorates experimental periodontitis in diabetic mice through negative regulation of TLR4 signaling. Acta Pharmacol Sin. Tamaki N, Orihuela-Campos RC, Inagaki Y, Fukui M, Nagata T, Ito HO. Free Radic Biol Med. Ikeda E, Ikeda Y, Wang Y, Fine N, Sheikh Z, Viniegra A, et al. Resveratrol derivative-rich melinjo seed extract induces healing in a murine model of established periodontitis. |
| Resveratrol Ameliorates Symptoms of Periodontal Disease - NHRI | The pharmacology of resveratrol in animals and humans. Biochim Biophys Acta. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. Cottart C-H, Nivet-Antoine V, and Beaudeux J-L. Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Mol Nutr Food Res. Soufi FG, Sheervalilou R, Vardiani M, Khalili M, and Alipour MR. Chronic resveratrol administration has beneficial effects in experimental model of type 2 diabetic rats. Endocr Regul. Zheng X, Zhu S, Chang S, Cao Y, Dong J, Li J, et al. Protective effects of chronic resveratrol treatment on vascular inflammatory injury in streptozotocin-induced type 2 diabetic rats: Role of NF-kappa B signaling. Eur J Pharmacol. Bhatt SR, Lokhandwala MF, and Banday AA. Resveratrol prevents endothelial nitric oxide synthase uncoupling and attenuates development of hypertension in spontaneously hypertensive rats. Breen DM, Dolinsky VW, Zhang H, Ghanim H, Guo J, Mroziewicz M, et al. Resveratrol inhibits neointimal formation after arterial injury through an endothelial nitric oxide synthase-dependent mechanism. Xuzhu G, Komai-Koma M, Leung BP, Howe HS, McSharry C, McInnes IB, et al. Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function. Ann Rheum Dis. Culpitt SV, Rogers DF, Fenwick PS, Shah P, De Matos C, Russell RE, et al. Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Culpitt SV, Rogers DF, Shah P, De Matos C, Russell RE, Donnelly LE, et al. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. Chung KO, Kim BY, Lee MH, Kim YR, Chung HY, Park JH, et al. In-vitro and in-vivo anti-inflammatory effect of oxyresveratrol from Morus alba L. J Pharm Pharmacol. Cichocki M, Paluszczak J, Szaefer H, Piechowiak A, Rimando AM, and Baer-Dubowska W. Pterostilbene is equally potent as resveratrol in inhibiting O-tetradecanoylphorbolacetate activated NFkappaB, AP-1, COX-2, and iNOS in mouse epidermis. Remsberg CM, Yanez JA, Ohgami Y, Vega-Villa KR, Rimando AM, and Davies NM. Pharmacometrics of pterostilbene: preclinical pharmacokinetics and metabolism, anticancer, antiinflammatory, antioxidant and analgesic activity. Phytother Res. McCormack D, Schneider J, McDonald D, and McFadden D. Am J Surg. Wang Y, Ding L, Wang X, Zhang J, Han W, Feng L, et al. Pterostilbene simultaneously induces apoptosis, cell cycle arrest and cyto-protective autophagy in breast cancer cells. Am J Transl Res. Ashraf MI, Shahzad M, and Shabbir A. Oxyresveratrol ameliorates allergic airway inflammation via attenuation of IL-4, IL-5, and IL expression levels. Yamamoto T, Li Y, Hanafusa Y, Yeh YS, Maruki-Uchida H, Kawakami S, et al. Piceatannol exhibits anti-inflammatory effects on macrophages interacting with adipocytes. Food Sci Nutr. Wang P, and Sang S. Metabolism and pharmacokinetics of resveratrol and pterostilbene. Hu N, Mei M, Ruan J, Wu W, Wang Y, and Yan R. Regioselective glucuronidation of oxyresveratrol, a natural hydroxystilbene, by human liver and intestinal microsomes and recombinant UGTs. Drug Metab Pharmacokinet. Jarosova V, Vesely O, Marsik P, Jaimes JD, Smejkal K, Kloucek P, et al. Metabolism of stilbenoids by human faecal microbiota. Dai Y, Lim JX, Yeo SCM, Xiang X, Tan KS, Fu JH, et al. Biotransformation of piceatannol, a dietary resveratrol derivative: promises to human health. Crowell JA, Korytko PJ, Morrissey RL, Booth TD, and Levine BS. Resveratrol-associated renal toxicity. Toxicol Sci. Ruiz MJ, Fernandez M, Pico Y, Manes J, Asensi M, Carda C, et al. Dietary administration of high doses of pterostilbene and quercetin to mice is not toxic. Riche DM, McEwen CL, Riche KD, Sherman JJ, Wofford MR, Deschamp D, et al. Analysis of safety from a human clinical trial with pterostilbene. J Toxicol. Kitada M, Ogura Y, Maruki-Uchida H, Sai M, Suzuki T, Kanasaki K, et al. The effect of piceatannol from passion fruit Passiflora edulis seeds on metabolic health in humans. Sale S, Verschoyle RD, Boocock D, Jones DJ, Wilsher N, Ruparelia KC, et al. Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4'-tetramethoxystilbene. Br J Cancer. Lin HS, Choo QY, and Ho PC. Quantification of oxyresveratrol analog trans-2,4,3',5'-tetramethoxystilbene in rat plasma by a rapid HPLC method: application in a pre-clinical pharmacokinetic study. Biomed Chromatogr. Lin HS, and Ho PC. Preclinical pharmacokinetic evaluation of resveratrol trimethyl ether in sprague-dawley rats: the impacts of aqueous solubility, dose escalation, food and repeated dosing on oral bioavailability. J Pharm Sci. Aldawsari FS, and Velazquez-Martinez CA. Invest New Drugs. Park HJ, Jeong SK, Kim SR, Bae SK, Kim WS, Jin SD, et al. Resveratrol inhibits Porphyromonas gingivalis lipopolysaccharide-induced endothelial adhesion molecule expression by suppressing NF-kappaB activation. Arch Pharm Res. Rizzo A, Bevilacqua N, Guida L, Annunziata M, Romano Carratelli C, and Paolillo R. Effect of resveratrol and modulation of cytokine production on human periodontal ligament cells. Casati MZ, Algayer C, Cardoso da Cruz G, Ribeiro FV, Casarin RC, Pimentel SP, et al. Resveratrol decreases periodontal breakdown and modulates local levels of cytokines during periodontitis in rats. Tamaki N, Cristina Orihuela-Campos R, Inagaki Y, Fukui M, Nagata T, and Ito HO. Free Radic Biol Med. Correa MG, Pires PR, Ribeiro FV, Pimentel SZ, Casarin RC, Cirano FR, et al. J Periodontal Res. Ben Lagha A, Andrian E, and Grenier D. Resveratrol attenuates the pathogenic and inflammatory properties of Porphyromonas gingivalis. Zhen L, Fan DS, Zhang Y, Cao XM, and Wang LM. Resveratrol ameliorates experimental periodontitis in diabetic mice through negative regulation of TLR4 signaling. Acta Pharmacol Sin. Casper RF, Quesne M, Rogers IM, Shirota T, Jolivet A, Milgrom E, et al. Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol Pharmacol. Singh SU, Casper RF, Fritz PC, Sukhu B, Ganss B, Girard BJr, et al. Inhibition of dioxin effects on bone formation in vitro by a newly described aryl hydrocarbon receptor antagonist, resveratrol. J Endocrinol. Andreou V, D'Addario M, Zohar R, Sukhu B, Casper RF, Ellen RP, et al. Inhibition of osteogenesis in vitro by a cigarette smoke-associated hydrocarbon combined with Porphyromonas gingivalis lipopolysaccharide: reversal by resveratrol. Ribeiro FV, Pino DS, Franck FC, Benatti BB, Tenenbaum H, Davies JE, et al. Resveratrol inhibits periodontitis-related bone loss in rats subjected to cigarette smoke inhalation. O'Connor DJ, Wong RW, and Rabie AB. Resveratrol inhibits periodontal pathogens in vitro. He Z, Huang Z, Zhou W, Tang Z, Ma R, and Liang J. Anti-biofilm activities from resveratrol against Fusobacterium nucleatum. Front Microbiol. Millhouse E, Jose A, Sherry L, Lappin DF, Patel N, Middleton AM, et al. Development of an in vitro periodontal biofilm model for assessing antimicrobial and host modulatory effects of bioactive molecules. BMC Oral Health. Cirano FR, Casarin RC, Ribeiro FV, Casati MZ, Pimentel SP, Taiete T, et al. Effect of Resveratrol on periodontal pathogens during experimental periodontitis in rats. Braz Oral Res. Joung DK, Mun SH, Choi SH, Kang OH, Kim SB, Lee YS, et al. Antibacterial activity of oxyresveratrol against methicillin-resistant Staphylococcus aureus and its mechanism. Exp Ther Med. Lee W, Basri D, and Ghazali A. Bactericidal effect of pterostilbene alone and in combination with gentamicin against human pathogenic bacteria. Yang S-C, Tseng C-H, Wang P-W, Lu P-L, Weng Y-H, Yen F-L, et al. Pterostilbene, a methoxylated resveratrol derivative, efficiently eradicates planktonic, biofilm, and intracellular MRSA by topical application. Ren X, An P, Zhai X, Wang S, and Kong Q. The antibacterial mechanism of pterostilbene derived from xinjiang wine grape: a novel apoptosis inducer in Staphyloccocus aureus and Escherichia coli. Lee JH, Cho HS, Joo SW, Chandra Regmi S, Kim JA, Ryu CM, et al. Diverse plant extracts and trans-resveratrol inhibit biofilm formation and swarming of Escherichia coli OH7. Qin N, Tan X, Jiao Y, Liu L, Zhao W, Yang S, et al. RNA-Seq-based transcriptome analysis of methicillin-resistant Staphylococcus aureus biofilm inhibition by ursolic acid and resveratrol. Sci Rep. Subramanian M, Goswami M, Chakraborty S, and Jawali N. Resveratrol induced inhibition of Escherichia coli proceeds via membrane oxidation and independent of diffusible reactive oxygen species generation. Redox Biol. Hwang D, and Lim YH. Resveratrol antibacterial activity against Escherichia coli is mediated by Z-ring formation inhibition via suppression of FtsZ expression. Kumar SN, Siji JV, Nambisan B, and Mohandas C. Activity and synergistic interactions of stilbenes and antibiotic combinations against bacteria in vitro. World J Microbiol Biotechnol. Ferreira C, Soares DC, Nascimento MT, Pinto-da-Silva LH, Sarzedas CG, Tinoco LW, et al. Resveratrol is active against Leishmania amazonensis: in vitro effect of its association with Amphotericin B. Antimicrob Agents Chemother. Joung DK, Choi SH, Kang OH, Kim SB, Mun SH, Seo YS, et al. Synergistic effects of oxyresveratrol in conjunction with antibiotics against methicillin-resistant Staphylococcus aureus. Mol Med Report. Helen Chan O, and Stewart BH. Physicochemical and drug-delivery considerations for oral drug bioavailability. Drug Discov Today. Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, and Beaudeux JL. Resveratrol bioavailability and toxicity in humans. Asensi M, Medina I, Ortega A, Carretero J, Bano MC, Obrador E, et al. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, and Ducharme MP. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, and Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. Das S, Lin HS, Ho PC, and Ng KY. The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol. Pharm Res. Chen W, Yeo SCM, Elhennawy MGAA, and Lin H-S. Oxyresveratrol: a bioavailable dietary polyphenol. J Funct Foods. C — Mei M, Ruan JQ, Wu WJ, Zhou RN, Lei JP, Zhao HY, et al. In vitro pharmacokinetic characterization of mulberroside A, the main polyhydroxylated stilbene in mulberry Morus alba L. Lin HS, Yue BD, and Ho PC. Determination of pterostilbene in rat plasma by a simple HPLC-UV method and its application in pre-clinical pharmacokinetic study. Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, and McCormick DL. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol. Yeo SC, Ho PC, and Lin HS. Pharmacokinetics of pterostilbene in Sprague-Dawley rats: the impacts of aqueous solubility, fasting, dose escalation, and dosing route on bioavailability. Choo Q-Y, Yeo SCM, Ho PC, Tanaka Y, and Lin H-S. Pterostilbene surpassed resveratrol for anti-inflammatory application: potency consideration and pharmacokinetics perspective. Roupe KA, Remsberg CM, Yanez JA, and Davies NM. Pharmacometrics of stilbenes: seguing towards the clinic. Curr Clin Pharmacol. Li HL, Wang AB, Huang Y, Liu DP, Wei C, Williams GM, et al. Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathways. Gao G, Chen L, Li J, Zhang D, Fang Y, Huang H, et al. Yeo SCM, Fenwick PS, Barnes PJ, Lin HS, and Donnelly LE. Isorhapontigenin, a bioavailable dietary polyphenol, suppresses airway epithelial cell inflammation through a corticosteroid-independent mechanism. Br J Pharmacol. Hasiah AH, Ghazali AR, Weber JF, Velu S, Thomas NF, and Inayat Hussain SH. Cytotoxic and antioxidant effects of methoxylated stilbene analogues on HepG2 hepatoma and Chang liver cells: implications for structure activity relationship. Hum Exp Toxicol. Lin JH, and Lu AY. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev. Bethune SJ, Schultheiss N, and Henck J-O. Improving the poor aqueous solubility of nutraceutical compound pterostilbene through cocrystal formation. Cryst Growth Des. Rubin LF. Toxicologic update of dimethyl sulfoxide. Ann NY Acad Sci. Notman R, Noro M, O'Malley B, and Anwar J. Molecular basis for dimethylsulfoxide DMSO action on lipid membranes. J Am Chem Soc. de Menorval MA, Mir LM, Fernandez ML, and Reigada R. Effects of dimethyl sulfoxide in cholesterol-containing lipid membranes: a comparative study of experiments in silico and with cells. PLoS ONE. Hanslick JL, Lau K, Noguchi KK, Olney JW, Zorumski CF, Mennerick S, et al. Dimethyl sulfoxide DMSO produces widespread apoptosis in the developing central nervous system. Neurobiol Dis. Sumida K, Igarashi Y, Toritsuka N, Matsushita T, Abe-Tomizawa K, Aoki M, et al. Effects of DMSO on gene expression in human and rat hepatocytes. Julien C, Marcouiller F, Bretteville A, El Khoury NB, Baillargeon J, Hebert SS, et al. Dimethyl sulfoxide induces both direct and indirect tau hyperphosphorylation. Galvao J, Davis B, Tilley M, Normando E, Duchen MR, and Cordeiro MF. Unexpected low-dose toxicity of the universal solvent DMSO. FASEB J. Verheijen M, Lienhard M, Schrooders Y, Clayton O, Nudischer R, Boerno S, et al. DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitro. Stella VJ, and He Q. Toxicol Pathol. Loftsson T, and Brewster ME. Pharmaceutical applications of cyclodextrins: basic science and product development. di Cagno M. The potential of cyclodextrins as novel active pharmaceutical ingredients: a short overview. Braga SS. Cyclodextrins: emerging medicines of the new millennium. Loftsson T, and Duchene D. Cyclodextrins and their pharmaceutical applications. Int J Pharm. Davis ME, and Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Ueda H, and Endo T. Large-Ring Cyclodextrins. Cyclodextrins and Their Complexes. Weinheim: WILEY-VCH Stella VJ, Rao VM, Zannou EA, and Zia VV. Mechanisms of drug release from cyclodextrin complexes. Adv Drug Del Rev. The work cannot be used commercially without permission from the journal. Click here to read the full text study. Chrystal Moulton BA, PMP , is a graduate of the University of Illinois at Chicago. She currently resides in Indianapolis, IN. Donate Newsletter Events Contact Us. Resveratrol Ameliorates Symptoms of Periodontal Disease by Becky Oct 26, , Oral Health , Resveratrol. Posted October 26, References: Pinto-Filho JM, Ribeiro LSF, Sartori L, Dos Santos JN, Ramalho LMP, Cury PR. Association between alcohol dependence and both periodontal disease and tooth loss: a cross-sectional study. Environmental science and pollution research international. Oct ;25 29 The effect of periodontal disease treatment in patients with continuous ambulatory peritoneal dialysis. Int Urol Nephrol. Aug ;50 8 Can Resveratrol Treatment Control the Progression of Induced Periodontal Disease? A Systematic Review and Meta-Analysis of Preclinical Studies. Apr 26 ;11 5 doi Kassebaum NJ, Bernabe´ E, Dahiya M, Bhandari B, Murray CJL, Marcenes W. Global burden of severe periodontitis in — a systematic review and meta-regression. J Dent Res ;— Khazaei S, Khazaei M, Kazemi S, Yaghini J. Resveratrol as a supplemental treatment for periodontitis. Dent Res J Isfahan. Czesnikiewicz-Guzik M, Nosalski R, Mikolajczyk TP, Vidler F, Dohnal T, DembowskaE, Graham D, Harrison DG, Guzik TJ. Th1-type immune responses to Porphyromonas gingivalis antigens exacerbate angiotensin II-dependent hypertension and vascular dysfunction. Br J Pharmacol ;— Treatment of periodontitis and endothelial function. N Engl J Med ;— Association between periodontal disease and its treatment, flow-mediated dilatation and carotid intima-media thickness: a systematic review and meta-analysis. Atherosclerosis ;— Cheng R, Wu Z, Li M, Shao M, Hu T. Interleukin-1β is a potential therapeutic target for periodontitis: a narrative review. Int J Oral Sci. Agnihotri R, Pandurang P, Kamath SU, et al. |
| Healing effects of monomer and dimer resveratrol in a mouse periodontitis model | As expected, suture ligated mice not treated with either formulation of resveratrol continued to lose bone until the last experimental day. Consent for publication Not applicable. However, in vitro data still constitute the bulk of current evidence, while the experimental studies available were largely conducted by a single research group. Journal of Biological Chemistry. Two key features of the methodology should be kept in mind when interpreting the results of this study. Glycolytic overload-driven dysfunction of periodontal ligament fibroblasts in high glucose concentration, corrected by glyoxalase 1 inducer. |
0 thoughts on “Resveratrol and dental health”